 |
인쇄하기
취소
|
Ilyang’s new leukemia drug shows promise
Ilyang Pharmaceutical Co. says it will carry out a Phase III clinical trial of radotinib, a new leukemia medicine.
The drug is believed to be 30 times more effective than Gleevec, a popular anti-leukemia medicine.
If successful, it is expected to change the landscape of the leukemia drug market dominated by multinational drug firms.
The drug showed differing levels of efficacy dependi...
The drug is believed to be 30 times more effective than Gleevec, a popular anti-leukemia medicine.
If successful, it is expected to change the landscape of the leukemia drug market dominated by multinational drug firms.
The drug showed differing levels of efficacy dependi...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.